 |
Previous Article | Next Article 
Journal of Neuroscience, Vol 15, 731-736, Copyright © 1995 by Society for Neuroscience
Sigma ligands indirectly modulate the NMDA receptor-ion channel complex on intact neuronal cells via sigma 1 site
H Yamamoto, T Yamamoto, N Sagi, V Klenerova, K Goji, N Kawai, A Baba, E Takamori and T Moroji
Department of Psychopharmacology, Tokyo Institute of Psychiatry, Japan.
To investigate the modulatory effects of sigma ligands on the N-methyl-
D-aspartate (NMDA) receptor-ion channel complex in vivo, we examined the
intact cell binding of 3H-N-[1-(2-thienyl)cyclohexyl]piperidine (3H- TCP)
to cultured neuronal cells prepared from fetal rat telencephalon. The
3H-TCP binding was saturable, reversible, and inhibited by a selective NMDA
receptor antagonist, D-amino-5-phosphonovaleric acid. MII-limolar Mg2+
inhibited 3H-TCP binding both in the absence and presence of L-glutamate.
5-Methyl-10,11-dihydro-5H-dibenzo [a,d]cyclohepten-5,10-imine maleate
(MK801) inhibited 3H-TCP intact cell binding in a competitive manner, while
haloperidol inhibited it in a noncompetitive manner. The effect of the test
drugs to inhibit 3H-TCP intact cell binding was in the order of
dextromethorphan, haloperidol > (+/-)MK 801 > (+)pentazocine >
(-)pentazocine > DTG > PCP > (+)-N- allylnormetazocine [(+)SKF
10047] > (+)3-(3-hydroxyphenyl)-N- (1- propyl)piperidine [(+)3-PPP] >
(-)SKF 10047 > (-)3-PPP. The IC50 values of the six sigma ligands for
3H-TCP binding were closely correlated with the Ki values of the
corresponding drugs for DTG site 1 in the guinea pig brain reported by
Rothman et al. (1991). These findings suggest that the sigma ligand
indirectly modulates the NMDA receptor ion channel complex, presumably
through sigma 1 sites in vivo as well as in vitro.
This article has been cited by other articles:

|
 |

|
 |
 
Y. Dun, M. Thangaraju, P. Prasad, V. Ganapathy, and S. B. Smith
Prevention of Excitotoxicity in Primary Retinal Ganglion Cells by (+)-Pentazocine, a Sigma Receptor-1 Specific Ligand
Invest. Ophthalmol. Vis. Sci.,
October 1, 2007;
48(10):
4785 - 4794.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Martina, M.-E. B. Turcotte, S. Halman, and R. Bergeron
The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus
J. Physiol.,
January 1, 2007;
578(1):
143 - 157.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Jiang, B. Mysona, Y. Dun, J. P. Gnana-Prakasam, N. Pabla, W. Li, Z. Dong, V. Ganapathy, and S. B. Smith
Expression, Subcellular Localization, and Regulation of Sigma Receptor in Retinal Muller Cells
Invest. Ophthalmol. Vis. Sci.,
December 1, 2006;
47(12):
5576 - 5582.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Vagnerova, P. D. Hurn, A. Bhardwaj, and J. R. Kirsch
Sigma 1 receptor agonists act as neuroprotective drugs through inhibition of inducible nitric oxide synthase.
Anesth. Analg.,
August 1, 2006;
103(2):
430 - 4, table of contents.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Goyagi, A. Bhardwaj, R. C. Koehler, R. J. Traystman, P. D. Hurn, and J. R. Kirsch
Potent {sigma}1-Receptor Ligand 4-Phenyl-1-(4-Phenylbutyl) Piperidine Provides Ischemic Neuroprotection Without Altering Dopamine Accumulation In Vivo in Rats
Anesth. Analg.,
February 1, 2003;
96(2):
532 - 538.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. R. Anderson and R. D. Andrew
Spreading Depression: Imaging and Blockade in the Rat Neocortical Brain Slice
J Neurophysiol,
November 1, 2002;
88(5):
2713 - 2725.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Goyagi, S. Goto, A. Bhardwaj, V. L. Dawson, P. D. Hurn, and J. R. Kirsch
Neuroprotective Effect of {{sigma}}1-Receptor Ligand 4-Phenyl-1-(4-Phenylbutyl) Piperidine (PPBP) Is Linked to Reduced Neuronal Nitric Oxide Production
Stroke,
July 1, 2001;
32(7):
1613 - 1620.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Engel, R. H. Purdy, and K. A. Grant
Characterization of Discriminative Stimulus Effects of the Neuroactive Steroid Pregnanolone
J. Pharmacol. Exp. Ther.,
April 12, 2001;
297(2):
489 - 495.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
I. Harukuni, A. Bhardwaj, A. B. Shaivitz, A. C. DeVries, E. D. London, P. D. Hurn, R. J. Traystman, J. R. Kirsch, and F. M. Faraci
{sigma}1-Receptor Ligand 4-Phenyl-1-(4-Phenylbutyl)-Piperidine Affords Neuroprotection From Focal Ischemia With Prolonged Reperfusion • Editorial Comment
Stroke,
April 1, 2000;
31(4):
976 - 982.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Millan, A. Newman-Tancredi, M. Brocco, A. Gobert, F. Lejeune, V. Audinot, J.-M. Rivet, R. Schreiber, A. Dekeyne, M. Spedding, et al.
S 18126 ({2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl}), a Potent, Selective and Competitive Antagonist at Dopamine D4 Receptors: An In Vitro and In Vivo Comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridine) and Raclopride
J. Pharmacol. Exp. Ther.,
October 1, 1998;
287(1):
167 - 186.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
E. R. Whittemore, V. I. Ilyin, and R. M. Woodward
Antagonism of N-Methyl-D-Aspartate Receptors by sigma Site Ligands: Potency, Subtype-Selectivity and Mechanisms of Inhibition
J. Pharmacol. Exp. Ther.,
July 1, 1997;
282(1):
326 - 338.
[Abstract]
[Full Text]
|
 |
|
|